Aurobindo Pharma Ltd. makes a corporate announcement

Aurobindo Pharma’s buyback reduced the equity base by 5,423,728 shares, or approximately 0.93%. The company’s shares fell from 580,801,623 to 575,377,895 at the Rs 1,475 buyback price; the buyback has since been completed and the shares extinguished ^{[1] [2]}.

EPS impact

The latest audited consolidated FY26 EPS was Rs 60.34 ^[3]. Assuming FY26 earnings are unchanged and the post-buyback share count is applied mechanically:

• Pro forma EPS = Rs 60.34 × 580,801,623 / 575,377,895
• Pro forma EPS: approximately Rs 60.91
• Increase: approximately Rs 0.57 per share, or 0.94% — derived from the audited EPS and pre/post-buyback share counts ^{[3] [2]}.

This is a pro forma calculation; FY26 statutory EPS itself is not restated because the buyback occurred after the March 31, 2026 year-end.

ROE impact

The latest audited FY26 consolidated ROE was 9.9% ^[4]. Since the buyback occurred after the FY26 year-end, the reported FY26 ROE remains unaffected. The mechanical impact should be positive because the buyback reduces equity, although the cash outflow also reduces the company’s net worth.

The company’s buyback financial-parameter table, based on the previous audited FY25 financials and assuming full acceptance, showed:

The disclosed calculation therefore indicated an improvement of 31 basis points in consolidated return on net worth and 36 basis points on a standalone basis ^[5]. These figures are FY25 pro forma disclosures, not revised FY26 audited ratios.

Conclusion: the share-count reduction provides roughly a 0.94% EPS accretion. ROE should also improve modestly as the equity denominator contracts, but the precise post-buyback FY26 ROE is not an audited reported metric; the company’s closest disclosed precedent was a 31 bp consolidated improvement.

The buyback has already moved through tendering and extinguishment. Aurobindo Pharma approved the Rs 800 Crores tender offer on 6 April 2026; the shares were extinguished on 14 May 2026. The offer covered up to 54,23,728 shares at Rs 1,475 per share, excluding transaction costs. ^[2]

Buyback timeline

The formal “Buyback Period” runs from the Board approval date until payment of consideration to shareholders whose shares were accepted. The exact payment date is not stated in the cited filings; the operating schedule specified settlement completion by 7 May 2026. ^{[8] [9]}

Debt-to-equity and related covenants

• Statutory leverage ceiling: After the buyback, aggregate secured and unsecured debt must not exceed 2x paid-up equity capital plus free reserves, including securities premium. The test is to be satisfied on both standalone and consolidated audited financial statements, using the 31 March 2025 balance sheet. ^[13]
• Disclosed post-buyback headroom: Assuming full acceptance, the reported total debt-to-equity ratio was 0.24x standalone and 0.27x consolidated, versus the statutory ceiling of 2.00x. The filing defines the ratio as total debt divided by net worth. ^{[5] [5]}
• Lender covenant consent: Because the company has outstanding lender facilities, it cannot proceed where a lender covenant breach requires consent unless prior lender consent has been obtained. Aurobindo stated that the necessary lender consents had been obtained. ^[14]
• No debt-funded buyback: The buyback was to be funded from free reserves, securities premium and other permitted internal resources; funds borrowed from banks or financial institutions were not to be used. ^[15]
• Solvency safeguard: Separately from the 2:1 leverage test, the Board represented that the company would be able to meet liabilities as they fell due and would not become insolvent within one year of the 6 April 2026 Board resolution. ^[16]

Key nuance: the cited covenant is framed as a post-buyback compliance test, not as a separately disclosed daily or interim debt-to-equity threshold during each tendering day. The reported 0.24x/0.27x ratios indicate substantial disclosed headroom under the 2:1 limit, but they are based on FY25 audited financials and a full-acceptance assumption rather than a live execution-period measurement. ^[14]

Rs 1,475 is substantially above Aurobindo Pharma’s latest book value, but its premium to the trailing 12-month VWAP cannot be established from the disclosed price data. Against FY26 consolidated book value per share of Rs 652.39 ^[17], the buyback price represents 2.26x book value, or a 126.09% premium, calculated from Rs 1,475 ^[2] and Rs 652.39 ^[17].

Buyback price versus VWAP

The buyback documentation reports a premium of 20.86% to the BSE three-month VWAP and 21.82% to the NSE three-month VWAP for the period preceding March 31, 2026 ^[18]. It does not report a trailing 12-month VWAP. A 12-month VWAP cannot be calculated from monthly closing prices alone because it requires daily price-volume data.

As a market cross-check, Aurobindo closed at Rs 1,608 in the latest completed session on August 20, 2026. The buyback price is therefore 8.27% below that close, meaning the stock subsequently moved above the tender price.

Capital-allocation read-through

The structure is best viewed as an episodic cash return rather than a recurring dividend programme:

• The 2026 buyback covers 54,23,728 shares, or approximately 0.93% of outstanding equity, for a maximum consideration of Rs 800 Crores ^[18].
• The buyback was funded from free reserves and other permitted internal sources; bank or financial-institution borrowings were not intended to fund it ^[18].
• Aurobindo paid no dividend in FY25, but completed a previous buyback worth Rs 750 Crores during that year ^[19].
• For FY26, it paid an interim dividend of Rs 4 per share ^[19]. Against FY26 diluted EPS of Rs 60.34 ^[20], the implied DPS/EPS payout is 6.63%, derived.
• The disclosed buyback record shows a prior buyback settled on August 19, 2024 ^[18] and the current buyback extinguished in May 2026 ^[2]. This supports two disclosed buybacks in roughly 21 months, but not a longer-term frequency ranking.

Dividend comparison with the named pharma peers

The dividend ratios below are directional because the denominators differ: DPS/EPS for Aurobindo and Dr. Reddy’s, policy payout for Laurus, consolidated PAT for Lupin and standalone PAT for Cipla.

Bottom line: Aurobindo’s Rs 1,475 offer is priced at a large premium to accounting book value but was only explicitly benchmarked against a three-month, not 12-month, VWAP. Relative to large-cap peers such as Dr. Reddy’s, Lupin and Cipla, Aurobindo has historically used a lower recurring dividend payout and occasional buybacks rather than maintaining a high, predictable dividend stream. The evidence supports an episodic buyback strategy, but does not establish that Aurobindo’s buybacks are more frequent than those of its peers.

Comparability caveat: The structured KPI extract shows zero dividend for Aurobindo and Mankind in FY26, which conflicts with their respective annual reports recording Rs 4 and Rs 1 per share. The annual-report disclosures are used for the dividend read-through above ^{[32] [33] [34]}.